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Abstract
We evaluated the efficacy and tolerability of antibiotic regimens and optimal duration of therapy in complicated and uncomplicated forms of
spinal brucellosis. This is a multicentre, retrospective and comparative study involving a total of 293 patients with spinal brucellosis from 19
health institutions. Comparison of complicated and uncomplicated spinal brucellosis was statistically analysed. Complicated spinal brucellosis
was diagnosed in 78 (26.6%) of our patients. Clinical presentationwas found to be significantlymore acute, with fever andweight loss, in patients
in the complicated group. They had significantly higher leukocyte and platelet counts, erythrocyte sedimentation rates and C-reactive protein
levels, and lower haemoglobulin levels. The involvement of the thoracic spine was significantly more frequent in complicated cases.
Spondylodiscitis was complicated, with paravertebral abscess in 38 (13.0%), prevertebral abscess in 13 (4.4%), epidural abscess in 30 (10.2%),
psoas abscess in 10 (3.4%) and radiculitis in 8 (2.7%) patients. The five major combination regimens were: doxycycline 200 mg/day, rifampicin
600 mg/day and streptomycin 1 g/day; doxycycline 200 mg/day, rifampicin 600 mg/day and gentamicin 5 mg/kg; doxycycline 200 mg/day and
rifampicin 600 mg/day; doxycycline 200 mg/day and streptomycin 1 g/day; and doxycycline 200 mg/day, rifampicin 600 mg/day and
ciprofloxacin 1 g/day. There were no significant therapeutic differences between these antibiotic groups; the results were similar regarding the
complicated and uncomplicated groups. Patients weremostly treatedwith doxycycline and rifampicin with orwithout an aminoglycoside. In the
former subgroup, complicated cases received antibiotics for a longer duration than uncomplicated cases. Early recognition of complicated cases
is critical in preventing devastating complications. Antimicrobial treatment should be prolonged in complicated spinal brucellosis in particular.
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Introduction
Brucellosis, the most common bacterial zoonosis in the world,
is still endemic in many developing countries. Spinal involve-
ment in brucellosis is seen in 6–12% of cases and is the
foremost cause of the debilitating and disabling complications
[1–4]. The treatment regimens recommended by the World
Health Organization (WHO) for brucellosis consist of the
combination of doxycycline and rifampicin (both drugs admin-
istered for 6 weeks) or alternatively doxycycline plus strep-
tomycin. Complicated spinal brucellosis requires a prolonged
therapy (≥8 weeks), but the ideal treatment regimen and the
optimal duration of the antibiotics in these cases are not
known [5]. High relapse rates were reported in a previous
series, in spite of the prolonged antibiotic treatment, and the
role of surgery still remains controversial [6].
Complicated spinal brucellosis is a rare complication of
vertebral osteomyelitis, extending to neighbouring vertebrae
and the paravertebral and epidural spaces. Several case reports
and series presenting spondylodiscitis with abscesses have
been published in the literature [1,6]. However, treatment
options and the duration of therapy have not been evaluated
separately. The aim of this multicentre study was to assess the
efficacy and tolerability of commonly used antibiotic regimens,
and optimal duration of therapy in complicated and uncom-
plicated forms of spinal brucellosis.
Patients and Methods
We performed a multicentre, retrospective and comparative
study involving a total of 293 patients with spinal brucellosis
from 19 health institutions. Demographic and epidemiolog-
ical characteristics, clinical and laboratory findings of the
patients, methods used in laboratory diagnosis of disease,
antibiotic regimens and the course of treatment were
recorded. The comparison of two groups of patients with
complicated and uncomplicated spinal brucellosis was statis-
tically analysed.
The diagnosis of brucellosis with spinal involvement was
established according to the presence of all of the following
three criteria.
1. A clinical picture compatible with spondylodiscitis or
spondylitis.
2. Absence of any aetiology other than brucellosis that can
explain spinal involvement.
3. Microbiological evidence of brucellosis
a. Isolation of Brucella from blood or other body fluids or
tissue samples.
b. Serological evidence of the disease.
Serological diagnosis of the disease included the following.
1. A Wright’s seroagglutination test titre of 1/160 or higher.
2. Non-agglutinating antibodies measured using Coombs’ test
at a titre of 1/320 or higher.
3. Four-fold or greater rise in serum antibody titres measured
at least 2–3 weeks apart.
Definitions
1. Brucellosis: clinical findings in accordance with the disease,
along with the aforementioned microbiological evidence [7].
2. Classification: according to the duration of symptoms,
brucellosis was classified as acute (<8 weeks), subacute(8–
52 weeks) and chronic(>52 weeks) brucellosis [8].
3. Spinal brucellosis was defined as clinical and radiological or
scintigraphical evidence of inflammation of one or more
vertebrae and/or discitis in a patient with brucellosis. Any
extension of infection through paravertebral and epidural
spaces, the psoas muscle or radicles with/without neuro-
logical involvement is defined as complicated spinal brucel-
losis.
4. Therapeutic failure was assessed by clinical and laboratory
evaluation of patients in relation to the parameters of
continuation and/or deterioration of symptoms, absence of
a decline in ESR and CRP levels and worsened imaging
findings during treatment.
5. Relapse was defined as a recurrence or exacerbation of
pain, unexplained fever, night sweats, weight loss, re-eleva-
tion of ESR and CRP levels, new vertebral lesions and
recurrent bacteraemia.
6. Sequelae were defined as persistent pain, abnormal physical
findings or functional limitation for longer than 6 months
after treatment.
Statistical analysis
Data analysis was performed using SPSS 15.0 software. The
data were defined using numbers, percentages, average,
median, standard deviation and 1st–3rd quartiles. Normal
distribution of the continuous values was assessed by the
Kolmogorov–Smirnov test. The t- test was used for variables if
normally distributed and Mann–Whithney U-test if not. The
chi-squared and Fisher’s exact tests were used for comparison
of discrete variables; a p value of <0.05 was considered
statistically significant. Any variable having a p value of < 0.25
was selected as a candidate variable, and these variables
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(considered to be clinically significant) were analysed to
determine the factors affecting the success of the treatment.
Backward LR analysis was used to obtain the best model.
Variables with p < 0.10 were included in this model.
Results
A total of 293 patients with spinal brucellosis were enrolled in
this study. The ages of the patients ranged between 14 and
85 years (51.4  16.2) and 156 (53.2%) of them were male.
Out of 293 patients, 128 (43.7%) were employed within animal
husbandry, 231 (78.8%) were consuming unpasteurized raw
milk and dairy products, 24 (8.2%) were dealing with
veterinary care, and two (0.7%) were laboratory workers.
Patients were classified into the acute (n = 132, 45.1%),
subacute (n = 123, 42.0%) and chronic (n = 28, 9.6%) stages of
the disease. The mean duration of symptoms for all patients
was 21 weeks. The most common clinical symptoms among all
patients were backache (90.8%), debility (69.6%), arthralgia
(61.4%) and fever (58.4%). Hepatomegaly and splenomegaly
were determined in 13.0% (38 patients) and 10.9% (32
patients) of all patients, respectively. The standard tube
agglutination test (STA) was used in 291 patients; it was
positive at a titre of ≥1:160 in 283 (97.2%) patients.
Enzyme-linked immunosorbent assay (ELISA) was used for
the diagnosis of 16 (5.4%) patients. Blood culture was obtained
from 185 patients and Brucella spp. were isolated in 62 (33.5%)
of them. Among subtyped isolates, 32 isolates (51.6%) were
identified as B. melitensis and 15 isolates (24.2%) were B. abor-
tus. The rate of isolation of Brucella spp. from blood cultures
was 32.0% in complicated cases, compared with uncomplicated
cases (p < 0.05). Cultures from the abscess were obtained in
20 patients and yielded the pathogen in 10 samples (50.0%),
with five of them identified as B. melitensis.
Complicated spinal brucellosis was diagnosed in 78 (26.6%)
patients. The clinical presentation was found to be significantly
more acute (with fever and weight loss) in the complicated
group. Laboratory profiles of the complicated cases differed
from the uncomplicated cases. They had significantly higher
leukocyte and platelet counts, erythrocyte sedimentation rates
and C reactive protein levels compared with the uncompli-
cated cases. However, they had lower haemoglobin levels.
Demographic, clinical and laboratory characteristics of the two
groups are listed in Table 1.
The diagnostic imaging methods used in patients with spinal
brucellosis were MRI alone in 226 patients (77.1%), bone
scintigraphy alone in two patients (0.7%) and CT alone in two
patients (0.7%) out of 293 patients. More than one imaging
technique was performed in 63 (21.5%) patients (MRI and
scintigraphy in 34 patients, MRI and CT in 24 patients, and MRI,
CT and scintigraphy in five patients). Single regional involve-
ment of the spine was seen in 234 (79.9%) patients and 59
patients (21.1%) had diffuse involvement (>2 vertebral bodies).
Considering the involvement of a single vertebral body, the
lumbar region was the most frequent vertebral level (470/656,
71.6%), followed by the thoracic region (90, 13.7%), sacral
region (61, 9.2%) and cervical (35, 5.3%) region (Fig. 1). The
involvement of the thoracic spine was significantly more
frequent in complicated cases. Spondylodiscitis was compli-
cated with paravertebral abscess in 38 patients (13.0%),
prevertebral abscess in 13 patients (4.4%), epidural abscess
in 30 patients (10.2%), psoas abscess in 10 patients (3.4%) and
radiculitis in 8 (2.7%) patients.
Various antibiotics (rifampicin, doxycycline, ciprofloxacin,
trimetroprim and sulphamethoxazole, and aminoglycoside) and
their combinations are used in the treatment of spinal
brucellosis. The five major combination regimens were as
follows.
1. Doxycycline 200 mg/day, rifampicin 600 mg/day and strep-
tomycin 1 g/day (DRS).
2. Doxycycline 200 mg/day, rifampicin 600 mg/day and genta-
micin (DRG).
3. Doxycycline 200 mg/day and rifampicin 600 mg/day (DR).
4. Doxycycline 200 mg/day and streptomycin 1 g/day (DS).
5. Doxycycline 200 mg/day, rifampicin 600 mg/day and cipro-
floxacin 1 g/day (DRC).
There was no significant therapeutic difference between
these antibiotic groups; the results were similar regarding the
complicated and uncomplicated groups separately (Table 2).
Patients were mostly treated with doxycycline and rifampicin
with or without an aminoglycoside. These two combinations
were compared according to the duration of the antibiotic
therapy in patients with therapeutic success. Complicated
cases received antibiotics for a longer duration than uncom-
plicated cases (Table 3). The clinical and therapeutic charac-
teristics of the two groups are compared in Table 4. Patients
treated with DR were more likely to be chronic (p < 0.05) and
weight loss was present significantly more frequently in
patients treated with DR and an aminoglycoside.
Side-effects attributed to each antibiotic were evaluated
by the prescriber clinicians. Nausea and vomiting (n = 18;
6.1%) were the most frequently reported side-effects
(Table 5). Doxycycline was the most switched (n = 8)
antibiotic due to gastrointestinal intolerance (nausea, vom-
iting, oesophagitis, gastritis and abdominal pain). The side--
effects attributed to rifampicin that resulted in switching
were also due to gastrointestinal intolerance, and skin
eruptions reported in two patients. The new regimens
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(n = 10) included ciprofloxacin (n = 9) and/or trimethoprim/
sulphamethoxasole (n = 6) instead of the discontinued
antibiotic due to side-effects.
The average time for the resolution of clinical findings can
be described as follows: resolution of the fever after 6.5 days
(range, 1–45 days), erythrocyte sedimentation rate declined
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FIG. 1. The distribution of involvement of each vertebra according to the radiological imaging techniques in spinal brucellosis cases (n = 293).
Variable Group I (n = 78) Group II (n = 215) p-value
Mean age  SD, years 55.7  14.8 49.8  16.4 0.014
Male sex, n (%) 46 (59.0) 110 (51.5) 0.236
Risk factors, n (%)
Animal husbandry 32 (41.0) 96 (44.7) 0.573
Consumption of unpasteurized milk 58 (74.4) 173 (80.5) 0.239
Veterinary/laboratory worker 2 (2.6) 22 (10.2) 0.034
Symptoms and signs, n (%)
Fever 53 (67.9) 118 (54.9) 0.045
Debility 59 (75.6) 145 (67.4) 0.177
Lack of appetite 45 (57.7) 102 (47.4) 0.121
Sweating 46 (59.0) 119 (55.3) 0.580
Arthralgia 47 (60.3) 133 (61.9 0.803
Backache 67 (85.9) 199 (92.6) 0.081
Weight loss 29 (37.2) 50 (23.3) 0.018
Hepatomegaly 14 (17.9) 24 (11.2) 0.126
Splenomegaly 10 (12.8) 22 (10.2) 0.530
Disease classification, n (%)
Acute 46 (59.0) 86 (40.0) 0.004
Subacute 30 (38.5) 93 (43.3) 0.462
Chronic 2 (2.6) 26 (12.1) 0.014
Relapse 2 (2.6) 15 (7.0) 0.153
Other organ/system involvement, n (%)
Joint 5 (6.4) 32 (14.9) 0.054
Sacroiliac joint 6 (7.0) 45 (20.9) 0.008
Testicles 2 (2.6) 3 (1.4) 0.612
Others 5 (6.4) 2 (0.9) NS
Involvement of vertebral region, n (%)
Cervical 7 (8.9) 9 (4.2) 0.111
Thoracic 18 (23.1) 29 (13.5) 0.048
Lumbar 65 (83.3) 187 (86.9) 0.427
Sacral 15 (19.2) 41 (19.1) 0.975
Co-morbidities, n (%)
Diabetes mellitus 13 (16.7) 26 (12.1) 0.308
Chronic renal failure 0 (0.0) 4 (1.9) 0.577
Malignancy 2 (2.6) 2 (0.9) 0.289
Immunosupression 0 (0.0) 3 (1.4) 0.568
Hypertension 5 (6.4) 5 (2.3) 0.137
Other 9 (11.5) 14 (1.4) 0.612
Laboratory data (mean + SD)
Leukocyte (cells/mm3) 7460  2152 6785  2519 0.006
Haemoglobin (g/dL) 12.1  1.80 12.6  1.70 0.047
Platelet (cells/mm3) 293154  102317 251237  87403 0.001
Erythrocyte sedimentation rate (mm/hr) 51.55  27.8 42.97  26.6 0.018
C-reactive protein (mg/L) 45.7  43.3 29.7  33.0 0.003
Aspartate aminotranspherase (IU/mL) 29  16 35  30 0.296
Alanine aminotranspherase (IU/mL) 33  27 36  33 0.948
Lactate dehydrogenase (IU/mL) 245  102 253  150 0.402
Creatine phosphokinase (IU/mL) 91  118 63  46 0.582
Isolation of Brucella spp. from blood culturesa, n (%) 25 (32.1) 37 (17.2) 0.006
Brucella melitensis 13 (52.0) 19 (51.4) 0.960
Brucella abortus 9 (36.0) 6 (16.2) 0.074
aSixty-two patients were culture positive for Brucella spp., with 32 positive for B. melitensis and 15 positive for B. abortus.
TABLE 1. Comparison of demo-
graphics and clinical and laboratory
data for complicated (Group I) and
uncomplicated (Group II) spinal bru-
cellosis cases (n = 293)
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after 37.4 days (range, 1–330 days), and CRP normalized after
31.9 days of treatment. Radiological improvement was
observed after 165.5 days (range, 24–730 days) of treatment.
Therapeutic failure was reported in 23 patients (7.85%),
relapse was reported in 17 (5.8%) patients and sequelae were
reported in eight (2.7%) patients. The sequelae in patients with
brucellosis were as follows: five patients developed chronic
pain, one patient developed neurogenic bladder, one patient
developed paraplegia, and difficulty in walking was observed in
one patient. Death was reported in one patient.
Surgery was performed in 32 patients (41.0%) and percu-
taneous abscess drainage was performed in three (3.8%) of the
complicated cases. The surgical procedure consisted of open
abscess drainage in 18 (23.0%) of the complicated cases.
Laminectomy was performed in five cases (6.4%) and discec-
tomy in two (2.7%) out of 78 complicated cases. Other surgical
procedures performed were as follows: laminectomy plus
discectomy in two patients (2.7%), laminectomy plus open
abscess drainage in two patients (2.7%), discectomy plus open
abscess drainage in one patient (1.3%), and open abscess
drainage plus cordectomy in one patient (1.3%).
Discussion
Brucellosis is an endemic zoonotic disease prevalent in rural
areas of Turkey [9]. Although many organs and systems may be
involved, osteoarticular disease is the most common compli-
cation in brucellosis [1–4]. This is a multicentre study of 293
patients with spinal brucellosis from different regions of the
country.
Clinical presentations of the patients were mostly acute or
subacute, as the mean duration of symptoms was 21 weeks.
Currently, due to widespread use of imaging techniques,
most patients are diagnosed in the early stages of the disease,
in contrast to previous studies reporting subacute or chronic
presentation [10]. As the corpus vascularization is insufficient,
[11] older patients are more prone to spinal involvement and
also contagious complications. The average age of our
patients was 51 years. Moreover, patients in the complicated
group were significantly older than those in the uncompli-
cated group.
The disease can affect the entire vertebral column and,
similarly to previous studies, the lumbar region was the most
frequently involved vertebral region, followed by the thoracic,
sacral and cervical regions. Multiple and contagious involve-
ment of vertebral bodies, which has been known to suggest
particularly tuberculous spondylodiscitis [12], was detected in
one-fifth of our cases as well. Brucellar involvement of multiple
vertebral bodies was reported to be around 9–30% in previous
studies [13,14]. Infection extending from the vertebrae to the
neighbouring tissues, including epidural and para-prevertebral
tissues, psoas muscles and radicles, was detected in a quarter
TABLE 2. Comparison of success of antibiotic regimens in
complicated and uncomplicated spinal brucellosis
Patient groups Regimens Successful, n (%) Failure, n (%) p-value
Uncomplicated
(n = 215)
DS 5 (100) 0 (0.0) 0.470
DRS 94 (92.2) 8 (8.8)
DRG 14 (100) 0 (0.0)
DRC 6 (85.7) 1 (14.3)
DR 70 (90.9) 7 (9.1)
Others 9 (90) 1 (10)
Complicated
(n = 78)
DS 2 (66.6) 1 (33.3) 0.816
DRS 36 (92.3) 3 (7.7)
DRG 8 (100) 0 (0.0)
DRC 4 (100) 0 (0.0)
DR 17(94.4) 1 (5.6)
Othersa 5 (83.3) 1 (6.7)
D, doxycycline; S, streptomycin; R, rifampicin; G, gentamicin; C, ciprofloxacin.
aOther: DR plus trimethoprim/sulphamethoxasole or ceftriaxone.
TABLE 3. Comparison of durations of successful antibiotic
regimens between groups (n = 239)
Patient groups
DR, median week
(1st–3rd quartiles)
DR plus
aminoglycoside,
median week
(1st–3rd quartiles) p-value
Complicated
(n = 61)
16 (12–23) 20 (12–35) 0.130
Uncomplicated
(n = 178)
12 (12–13.25) 12 (12–16) 0.876
p-value 0.241 0.001
D, doxycycline; R, rifampicin; aminoglycoside, gentamicin or streptomycin.
TABLE 4. Comparison of demographics and clinical, micro-
biological and treatment data of spinal brucellosis cases
according to the two main antibiotic regimens (n = 258)
Variable DR (n = 95)
DR plus
aminoglycoside
(n = 163) p-value
Female gender, n (%) 45 (47.4) 92 (56.4) 0.159
Mean age  SD, years 49.6  17.9 51.5  15.2 0.537
Duration of symptoms,
median weeks
(1st–3rd quartile)
12 (6.75–24.0) 12 (4.0–20.0) 0.267
Disease classification, n (%)
Acute 39 (41.1) 73 (44.8) 0.560
Subacute 34 (35.8) 76 (46.6) 0.090
Chronic 17 (17.9) 10 (6.1) 0.003
Relapse 7 (7.4) 8 (4.9) 0.415
Isolation of Brucella spp.
from blood or abscess
24 (25.3) 31 (19.0) 0.237
Symptoms and signs, n (%)
Fever 56 (58.9) 95 (58.3) 0.917
Fatigue 64 (67.4) 118 (72.4) 0.393
Lack of appetite 47 (49.5) 82 (50.3) 0.897
Sweating 56 (58.9) 89 (54.6) 0.497
Back pain 89 (93.7) 148 (90.8) 0.413
Weight loss 13 (13.7) 52 (31.9) 0.001
Hepatomegaly 12 (12.6) 20 (12.3) 0.932
Splenomegaly 12 (12.6) 16 (9.8) 0.483
Paravertebral abscess, n (%) 17 (18.1) 39 (24.5) 0.233
Spinal surgery needed, n (%) 8 (8.4) 20 (12.3) 0.338
Treatment failure, n (%) 8 (8.4) 11 (6.7) 0.620
Sequelae, n (%) 3 (3.2) 3 (1.8) 0.672
Aminoglycoside, gentamicin or streptomycin.
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of the patients with spinal involvement. Similar manifestations
of spinal involvement are observed both in tuberculosis and
brucellosis; furthermore, these diseases are endemic and
important public health problems in Turkey.
Serology is the leading diagnostic tool in brucellosis and thus
almost all patients in this study had a positive tube agglutination
test. These basic tests should be considered and performed as
an initial step in the differential diagnosis of spondylodiscitis
[8]. On the other hand, the isolation of the organism from
either blood or tissue culture is the definite diagnosis of the
disease as seronegative cases have been reported [15].
Seronegative sponylodiscitis seems to be a rare entity and
was only detected in eight (2.7%) patients in this study. As the
bacteraemia is intermittent and the previously reported
prevalence in the literature is 41–56% depending on the
timing of the culture[13], the blood cultures yielded positive
results in one-third of our patients. Although B. melitensis,
which is the most virulent of all species of Brucella, was the
prominent strain identified, B. abortus was also considerably
common, being associated with a quarter of cases.
Antibiotics are the mainstay of brucellosis treatment, with
combinations recommended to prevent the high relapse rates
reported with monotherapy. Several dual or triple antibiotic
combinations for spinal brucellosis have been compared in
different studies [1–3,16–19]. The most frequently proposed
and used combinations include streptomycin. Despite the
known side-effects of streptomycin, favourable results were
reported in brucellosis with bone and joint involvement.
Ototoxicity and dizziness were the most prominent side-
effects of the drugs among our patients. However, they were
not switched due to the short-term utilization and reversibility
of the side-effects after the discontinuation of the drug.
Clinicians may particularly hesitate to treat the disease with
streptomycin in the elderly because they are more prone to
side-effects. The restricted use of a parenterally administrated
drug in clinical practice is another disadvantage of the
treatment. On the other hand, streptomycin in combination
with doxycycline was reported to have a superior efficacy and
lower relapse rates [3,20]. Doxycycline is the backbone of the
antimicrobial treatment and it was included in all regimens in
our study. However, rather than streptomycin, doxycycline
was the most intolerable and switched drug. A triple combi-
nation of DRS was used most commonly in our study. After
discontinuing streptomycin treatment, patients were treated
with DR instead of doxycycline monotherapy. However, the
utilization of rifampicin and streptomycin, which are also
effective against M. tuberculosis, poses the risk of increased
mycobacterial resistance in an endemic area. On the other
hand, DR was a commonly preferred oral option that was as
effective as streptomycin combinations. However, interactions
limiting the effectiveness of this combination were previously
reported [20]. Combinations including ciprofloxacin were also
found to be effective and were proposed as an alternative to
these standard regimens, which had higher costs [21]. Ten of
our patients were treated successfully with the combinations
including ciprofloxacin and it was used as an alternative to
problematic drugs just after switching. Our study represents
the clinical experience of infectious disease specialists in the
treatment of spinal brucellosis in an endemic area and five
major combinations were compared in this paper. However,
none of these combinations demonstrated superiority in terms
of therapeutic success in both complicated and uncomplicated
cases.
Patients with spinal brucellosis do not constitute a homog-
enous group. Complicated spinal brucellosis extending to
neighbouring tissue and paravertebral and epidural spaces has
been believed to be a relatively rare complication of vertebral
osteomyelitis [16,22]. Several case reports and series pre-
senting spondylodiscitis with abscesses have been published
[1–3,16,18,22]. However, characteristics, treatment options
and the duration of the therapy have not been separately
evaluated before. One of the objectives of this study was
to compare clinical characteristics and the treatment of
complicated spinal brucellosis with uncomplicated cases.
Side-effects Rifampicin Doxycycline Streptomycin Ciprofloxacin
Trimethoprim/
sulphamethoxasol Total
Nausea and
vomiting
2 14 1 1 18
Hepatotoxicity 3 3
Oesophagitis 2 2
Gastritis 1 1
Skin eruptions 3 4 2 2 11
Thrombo
cytopenia
1 1
Autotoxicity 3 3
Abdominal pain 1 1
Facial numbness 1 1
Dizziness 3 3
Total (n) 9 22 8 2 3 44
TABLE 5. Side-effects attributed to
antibiotics used in the treatment of
spinal brucellosis
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Complicated cases were detected in a quarter of our patients,
and this was a much higher percentage than the rates reported
by previous authors. The complicated group of patients was
significantly older and was diagnosed more frequently at the
acute stage. In contrast, uncomplicated cases were more
commonly diagnosed at the chronic stage Accordingly, positive
blood cultures were significantly more common among the
complicated cases. Thus, these cases seem to manifest with
severe symptoms in the acute and bacteraemic period of the
disease. Likewise, laboratory findings were more remarkable,
more anaemic and with higher levels of acute phase reactants.
Although the lumbar vertebrae were the most frequent site of
involvement, the thoracic region was affected more signifi-
cantly in complicated cases.
In case series including patients with paraspinal abscess it
was reported that patients were treated for a longer
duration depending on the clinical and radiological response
[1]. In this study, the duration of treatment was not
significantly different between patients treated with DR and
those treated with aminoglycoside-including combinations.
However, we found that in the DR plus an aminoglycoside
arm, the complicated cases needed a longer treatment.
Criteria for the response to treatment were resolution of
fever within the first week and normalization of CRP level
within the first month. Improvement in radiological findings
was the final criterion, achieved after an average period of
23 weeks. A recent study showed that the effective
treatment should be a triple antibiotic regimen given for a
prolonged period of time (minimum 24 weeks). In this small
series of patients with spondylitis, all patients achieved
complete remission without relapse or sequelae [19]. Given
the fact that brief courses of treatment were reported to
result in frequent relapses, duration of treatment appears to
be a more important issue than antibiotic selection, accord-
ing to our data.
The role of surgery is another controversial issue in these
patients and in most cases medical treatment is adequate for
cure. Surgery was performed in two-fifths of our complicated
cases. Aspiration of abscess may provide pain relief and
sampling for differential diagnosis and this sampling was
performed in most of our patients who underwent surgery.
Surgical interventions are proposed as the last resort in the
case of continuing systemic signs despite adequate antimicro-
bial therapy, vertebral collapse or septal abscess[14].
In conclusion, antimicrobial treatment should be prolonged
in complicated spinal forms of brucellosis. Early recognition of
complicated cases is critical in preventing devastating compli-
cations. Selection of an appropriate antibiotic combination
should be made on the basis of the patient and the population:
age, side-effects and ease of application. As MRI provides
satisfactory information in the early stages of the disease, it
should be repeated at the end of the fourth month of
treatment.
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